Subscribe: Latest / All - Designed by Dr James P Howard (Google+)
CORONA TRIAL |
|
|---|---|
| Problem | CCF (EF < 40%, NYHA II) |
| Format | Multicenter, double-blind, randomized placebo-controlled trial |
| Treatment | Low-dose Rosuvastatin (10mg) |
| Control | Placebo |
| Population | 5,011 patients |
| Inclusion criteria | Age >60 years Ischemic CHF NYHA class II-IV symptoms LVEF <40% (or <35% with NYHA class II symptoms) No indication for cholesterol-lowering therapy Stable on optimal treatment for >2 weeks prior to randomization |
| Exclusion criteria | Prior statin-induced myopathy or hypersensitivity Decompensated CHF or need for inotropic support MI within past 6 months UA or stroke within past 3 months PCI, CABG, ICD, or BiV pacemaker within past 3 months or plan to implant Prior heart transplant Significant uncorrected primary valvular heart disease Malfunctioning prosthetic valve Hypertrophic cardiomyopathy Acute endomyocarditis/myocarditis Pericardial disease Systemic disease (eg, amyloidosis) Liver disease Serum Cr >2.5 mg/dL Chronic muscle disease or CPK > 2.5x ULN Prior cyclosporine Life-limiting condition limiting compliance with protocol Receipt of <80% placebo tablets during run-in period |
| Follow-up | Mean 2.7 years |
| Primary endpoint | Composite of cardiovascular death, nonfatal MI, or nonfatal stroke |
| Secondary endpoint(s) | All-cause mortality Coronary events Cardiovascular death |
| Details | . |
| Brief summary: | Rosuvastatin in statin-naive CCF patients reduced admissions but not mortality |
| PAPER: Rosuvastatin in older patients with systolic heart failure. | |
|---|---|
| Date | 29 Nov 2007 |
| Journal | N Engl J Med. 2007 Nov 29;357(22):2248-61. Epub 2007 Nov 5. |
| Information | In those with CCF and no other indication for statins, Rosuvastatin 10mg: -No improval in survival -Reduced hospital admissions (p<0.001) |